Pacific Biosciences of Ca... (PACB)
Pacific Biosciences of California Statistics
Share Statistics
Pacific Biosciences of California has 273.86M shares outstanding. The number of shares has increased by 2.21% in one year.
| Shares Outstanding | 273.86M |
| Shares Change (YoY) | 2.21% |
| Shares Change (QoQ) | 0.49% |
| Owned by Institutions (%) | 84.91% |
| Shares Floating | 243.51M |
| Failed to Deliver (FTD) Shares | 41.18K |
| FTD / Avg. Volume | 0.32% |
Short Selling Information
The latest short interest is 60.54M, so 22.11% of the outstanding shares have been sold short.
| Short Interest | 60.54M |
| Short % of Shares Out | 22.11% |
| Short % of Float | 25.03% |
| Short Ratio (days to cover) | 6.95 |
Valuation Ratios
The PE ratio is -1.63 and the forward PE ratio is -2.5. Pacific Biosciences of California's PEG ratio is 0.22.
| PE Ratio | -1.63 |
| Forward PE | -2.5 |
| PS Ratio | 3.26 |
| Forward PS | 1.1 |
| PB Ratio | 0 |
| P/FCF Ratio | 0 |
| PEG Ratio | 0.22 |
Enterprise Valuation
Pacific Biosciences of California Inc. has an Enterprise Value (EV) of 3.24B.
| EV / Earnings | -10.5 |
| EV / Sales | 21.05 |
| EV / EBITDA | -9.1 |
| EV / EBIT | -9.1 |
| EV / FCF | -12.1 |
Financial Position
The company has a current ratio of 0, with a Debt / Equity ratio of 0.
| Current Ratio | 0 |
| Quick Ratio | 0 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0 |
| Cash Flow / Debt | 0 |
| Interest Coverage | 26.57 |
Financial Efficiency
Return on equity (ROE) is 0% and return on capital (ROIC) is -21.82%.
| Return on Equity (ROE) | 0% |
| Return on Assets (ROA) | 0% |
| Return on Capital (ROIC) | -21.82% |
| Revenue Per Employee | $193,484.92 |
| Profits Per Employee | $-387,752.51 |
| Employee Count | 796 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 316K |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -73.16% in the last 52 weeks. The beta is 1.86, so Pacific Biosciences of California's price volatility has been higher than the market average.
| Beta | 1.86 |
| 52-Week Price Change | -73.16% |
| 50-Day Moving Average | 1.71 |
| 200-Day Moving Average | 1.77 |
| Relative Strength Index (RSI) | 38.82 |
| Average Volume (20 Days) | 13M |
Income Statement
In the last 12 months, Pacific Biosciences of California had revenue of 154.01M and earned -308.65M in profits. Earnings per share was -1.12.
| Revenue | 154.01M |
| Gross Profit | 37.28M |
| Operating Income | -356.38M |
| Net Income | -308.65M |
| EBITDA | -356.38M |
| EBIT | -356.38M |
| Earnings Per Share (EPS) | -1.12 |
Balance Sheet
The company has 179.91M in cash and 933.93M in debt, giving a net cash position of -754.02M.
| Cash & Cash Equivalents | 179.91M |
| Total Debt | 933.93M |
| Net Cash | -754.02M |
| Retained Earnings | -1.84B |
| Total Assets | 1.26B |
| Working Capital | 439.86M |
Cash Flow
In the last 12 months, operating cash flow was -259.17M and capital expenditures -8.84M, giving a free cash flow of -268.02M.
| Operating Cash Flow | -259.17M |
| Capital Expenditures | -8.84M |
| Free Cash Flow | -268.02M |
| FCF Per Share | null |
Margins
Gross margin is 24.21%, with operating and profit margins of -231.4% and -200.4%.
| Gross Margin | 24.21% |
| Operating Margin | -231.4% |
| Pretax Margin | -200.2% |
| Profit Margin | -200.4% |
| EBITDA Margin | -231.4% |
| EBIT Margin | -231.4% |
| FCF Margin | -174.02% |
Dividends & Yields
PACB does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -85.5% |
| FCF Yield | -74.42% |
Analyst Forecast
The average price target for PACB is $2.5, which is 90.8% higher than the current price. The consensus rating is "Buy".
| Price Target | $2.5 |
| Price Target Difference | 90.8% |
| Analyst Consensus | Buy |
| Analyst Count | 13 |
Scores
| Altman Z-Score | -0.18 |
| Piotroski F-Score | 4 |